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with rosuvastatin, 235, 387 and 387 for 10-, 20-and 40-mg doses, respectively; with atorvastatin, 235, 387, 387 and 387 for 10-, 20-, 40-and 80-mg doses, respectively; with pravastatin, 211, 387 and 387 for 10-, 20-and 40-mg doses, respectively; with branded simvastatin, 235, 387, 387 and 387 for 10-, 20-, 40-and 80-mg doses, respectively; and with generic simvastatin, 156, 209, 274 and 375 for 10-, 20-, 40-and 80-mg doses, respectively. 
Synthesis of costs and benefits
The costs and benefits were combined using an incremental cost-effectiveness ratio (i.e. the additional cost per 1% reduction in LDL-C levels, or the additional cost per patient reaching European goals). The authors ranked all interventions by effectiveness and ruled out all those interventions that were either dominated (i.e. more expensive and less effective) or extended dominated (i.e. for a lower incremental cost-effectiveness ratio the comparator is more effective).
Compared with generic simvastatin 10 mg, the use of rosuvastatin 10 mg was associated with a cost of 4.48 per extra 1% reduction in LDL-C per patient, while the use of rosuvastatin 40 mg was associated with a cost of 8.64 per extra 1% reduction.
Compared with generic simvastatin 10 mg, the use of rosuvastatin 10 mg was associated with a cost of 162.04 per additional patient reaching LDL-C goals, while the use of rosuvastatin 20 mg was associated with a cost of 10.28 per additional patient.
The results of the sensitivity analysis showed that the cost-effectiveness results were robust to plausible variations in efficacy and substantial variation in price.
Authors' conclusions
In patients with hypercholesterolaemia, rosuvastatin was a cost-effective statin option for treating patients to lowdensity lipoprotein cholesterol (LDL-C) goals.
CRD COMMENTARY -Selection of comparators
The use of rosuvastatin as the comparator was justified on the grounds that trials had demonstrated it to have greater efficacy in lowering LDL-C levels than atorvastatin, pravastatin or simvastatin. You should decide if the comparator used represents current practice in your own setting.
Validity of estimate of measure of effectiveness
The analysis of effectiveness was based on an RCT. This was appropriate for the study question, as well-conducted RCTs are considered the 'gold' standard study design when comparing different health care interventions. However, the authors did not report the methods of the trial in detail, referring the reader instead to other publications for more information. The authors reported that all patient groups were shown to be comparable at baseline in terms of the target LDL-C levels to be achieved. Appropriate statistical analysis were undertaken to test for statistically significant differences between the groups. To fully assess the internal validity of the effectiveness measures the reader will need to consult the paper reporting the clinical study.
Validity of estimate of measure of benefit
The estimation of benefits was obtained directly from the effectiveness analysis, although the authors assumed that the efficacy of the different treatment options at 6 weeks was equivalent to that after one year. This assumption was not tested in sensitivity analysis. Ideally, the authors should have used a more generic health outcome (e.g. quality adjusted life-years or life-years gained) to make comparisons across different interventions in other disease areas.
